科学图书馆
-
Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?W Sumaya, RF Storey. -
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of theKedhi E, Fabris E, van der Ent M et al.
-
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCIK Takahashi, PW Serruys, P Chichareont et al.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
-
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionS-J Lee, JY Cho, TICO Investigators et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary InterventionDJ Angiolillo, U Baber, R Mehran et al.
-
Antibody-Based Ticagrelor Reversal Agent in Healthy VolunteersDL Bhatt, CV Pollack, JS Lee et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
